Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Evaluation of biochemical and economic outcomes in patients treated with PCSK9 inhibitors in a real clinical practice setting

Title: Evaluation of biochemical and economic outcomes in patients treated with PCSK9 inhibitors in a real clinical practice setting
Authors: Dovizio M.; Nugnes M.; Iacolare B.; Nappi C.; Saragoni S.; Andretta M.; Barbieri A.; Bartolini F.; Chinellato G.; Cillo M.; Dell'Orco S.; Grego S.; Lavalle A.; Procacci C.; Re D.; Degli Esposti L.
Contributors: Dovizio, M.; Nugnes, M.; Iacolare, B.; Nappi, C.; Saragoni, S.; Andretta, M.; Barbieri, A.; Bartolini, F.; Chinellato, G.; Cillo, M.; Dell'Orco, S.; Grego, S.; Lavalle, A.; Procacci, C.; Re, D.; Degli Esposti, L.
Publication Year: 2025
Collection: ARUd'A - Archivio Istituzionale della ricerca dell'università Chieti-Pescara (IRIS)
Subject Terms: Cardiovascular disease; Costs and cost analysi; Cholesterol; LDL; PCSK9 inhibitors
Description: BACKGROUND: PCSK9 inhibitors (PCSK9i) in combination with high-dose statins can reduce LDL-cholesterol (LDL-C) levels by 50-60% over statin monotherapy. This analysis investigated biochemical (LDL-C reduction) and economic outcomes in Italian patients treated with PCSK9i or potentially eligible but untreated. METHODS: Administrative databases of healthcare institutions covering around 5 million residents were used to identify patients with PCSK9i prescriptions or potentially eligible-untreated patients between 2017 and Oct-2022. Outcomes were assessed during follow-up in cohorts balanced for baseline covariates by propensity score matching (PSM). RESULTS: After PSM-balancing, 2649 treated and 2649 potentially eligible-untreated patients were included: mean age 64.4-64.7 years, 70-68% males, 92-93% with hypertension, 24-25% with diabetes, and 87% with previous atherosclerotic/cardiovascular events. During follow-up, PCSK9i-treated patients versus untreated/eligible showed a reduction of LDL-C levels (68.9 +/- 43.9 vs. 100.4 +/- 34.6 mg/dL, P
Document Type: article in journal/newspaper
Language: English
Relation: info:eu-repo/semantics/altIdentifier/pmid/40292681; info:eu-repo/semantics/altIdentifier/wos/WOS:001479766700001; volume:73; issue:4; firstpage:422; lastpage:431; numberofpages:10; journal:MINERVA CARDIOLOGY AND ANGIOLOGY; https://hdl.handle.net/11564/866177
DOI: 10.23736/S2724-5683.24.06626-2
Availability: https://hdl.handle.net/11564/866177; https://doi.org/10.23736/S2724-5683.24.06626-2
Accession Number: edsbas.CDDB251D
Database: BASE